The Adjuvant Part of Neoantigen Cancer Vaccines: No Clear Winner Has Yet Emerged

Time: 2:00 pm
day: Day Three Track A AM

Details:

• Exploring the use of a cell-based, allogeneic, immune primer for recruitment and activation of cross-presenting DCs
• Harnessing skin-resident memory CD8+ T cells for adaptive immune responses